Rachel Mcminn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesRachel mcminnHuman research ethics committeeNeurogene incAmerican society of geneDrug administrationExchange commissionResearch development rd expensesAustralian therapeutic goods administrationChief executive officerRecent highlightsAmerican societyCell therapyAnnual meetingAnnual goldman sachs global healthcare conferenceInternational rett syndrome foundation

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-up No signs or symptoms of overexpression toxicity, including in one patient with a mild.

United statesBernhard suterRachel mcminnAmerican society of geneCompany annual report on formExchange commissionNeurogene incAmerican societyCell therapyChief executive officerRett syndromeClinical global impression severityMedical directorBlue bird circle rett centerTexas childrenAssociate professor

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

NGN-401 has been generally well-tolerated by three patients with multiple months of follow-up .

United statesUnited kingdomRachel mcminnNeurogene incCompany annual report on formAmerican society for geneExchange commissionAmerican societyCell therapyChief executive officerPoster presentationPreliminary safety resultsNovel regulated gene therapyRett syndromeExhibit hallPrivate securities litigation reform act

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

22.04.2024 - Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing . Seite 1

United statesRachel mcminnAmerican society for geneNeurogene incAmerican societyCell therapyChief executive officer

Neurogene Announces Appointment of Julie Jordan, M D , as Chief Medical Officer

Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Julie.

United statesRachel mcminnHead of clinical developmentSecurities exchangeNeurogene incTeva pharmaceutical industriesNeoleukin therapeutics incDepartment of medicine at massachusettsAvanir pharmaceuticalsCompany current report on formHarvard collegeHarvard medical schoolJulie jordanChief medicalChief medical officerHomology medicines